Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.240
+0.007 (0.22%)
May 9, 2025, 4:00 PM - Market closed
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$229,677
Profits / Employee
-$335,634
Market Cap
17.34M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
LPCN News
- 1 day ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - PRNewsWire
- 3 days ago - Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PRNewsWire
- 6 weeks ago - Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - PRNewsWire
- 2 months ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - PRNewsWire
- 2 months ago - Lipocine Announces FDA Labeling Changes for Testosterone Products - PRNewsWire
- 3 months ago - Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PRNewsWire
- 5 months ago - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PRNewsWire
- 6 months ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire